Antibody Conjugate-Mediated Degradation
Advanced reagents and assays for comprehensive E3 ligase screening and profiling solutions
Need Help?
About: Antibody Conjugate-Mediated Degradation
Antibody conjugate-mediated degradation (AbTACs or PROTAbs) represents yet another innovative approach to targeted protein degradation. By coupling antibodies specific to cell surface proteins with molecules that induce degradation, this technique enables precise elimination of disease-causing proteins.
Offering a potent and highly specific therapeutic strategy, antibody conjugate-mediated degradation holds promise for treating a wide range of diseases with aberrant protein expression, including cancer and neurodegenerative disorders.
Technology Components
E3 Ligase Recruiter Antibody
Target Protein Binding Antibody
Our Unique Assays
LifeSensors offers unique and physiologically relevant target ubiquitination and degradation assays that allows rapid characterization of AbTACs/PROTAbs for their specificity and potency.
Accelerate Your Discovery
- Advantages of Choosing LifeSensors for Your PROTAC Drug Discovery
Simultaneous Analysis
Study PROTAC-mediated Ubiquitination and Degradation simultaneously
Complete Validation Suite
Complete suite of validation studies to establish binding, ternary complex formation, and cellular degradation
Novel E3 Ligases
Experience with novel E3 ligases – ~30 E3 ligases amenable to PROTAC discovery
Advanced Proteomics
Proteomics to characterize protein degradation – establish selectivity
- Resources
PROTAC Drug Discovery Presentation
Download our comprehensive presentation on PROTAC drug discovery methodologies and applications.
LifeSensors PROTAC Paper
Published research and findings
Extracellular Targeted Protein Degradation
An emerging modality for drug discovery